No matches
Dermatology

Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.
Amy Paller
MD, MS
Amy Paller

Related resources

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

videoanimation
What is Early Intervention in AD?

What is Early Intervention in AD?

expert video
Disease Modification in AD

Disease Modification in AD

expert video
Systemic Inflammation in AD – Beyond the Skin

Systemic Inflammation in AD – Beyond the Skin

expert video
Dysbiosis, Skin Infections, and Itch

Dysbiosis, Skin Infections, and Itch

expert video
Skin Barrier Dysfunction in AD

Skin Barrier Dysfunction in AD

expert video
Early Intervention and the Potential for Disease Modification in Children With AD

Early Intervention and the Potential for Disease Modification in Children With AD

expert video
Emerging Data on Advanced Systemic Treatments for Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

expert video
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

expert video
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

expert video
UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

expert video
UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

expert video
UCARE 2023: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

UCARE 2023: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

expert video
UCARE 2023: CSU – The Brazil Perspective

UCARE 2023: CSU – The Brazil Perspective

expert video
UCARE 2023: Panel Discussion/Q&A

UCARE 2023: Panel Discussion/Q&A

expert video
Comorbidities and Clinical Management in CSU

Comorbidities and Clinical Management in CSU

expert video
Comorbidities and Disease Burden in CSU

Comorbidities and Disease Burden in CSU

expert video
Treatment Goals, Current and Emerging Therapies in CSU

Treatment Goals, Current and Emerging Therapies in CSU

expert video
Guideline and Patient Management in CSU

Guideline and Patient Management in CSU

expert video
The Current and Potential Future Roles of Biomarkers and Precision Medicine in CSU Clinical Management

The Current and Potential Future Roles of Biomarkers and Precision Medicine in CSU Clinical Management

expert video
How Interdisciplinary Communication and Collaboration Can Overcome Challenges in CSU Patient Management

How Interdisciplinary Communication and Collaboration Can Overcome Challenges in CSU Patient Management

expert video
The Role of Chronic Inflammation in the Pathogenesis of CSU

The Role of Chronic Inflammation in the Pathogenesis of CSU

expert video
Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Infographic
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

expert video
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

expert video
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

expert video
A brief overview of the pathophysiology of PN

A brief overview of the pathophysiology of PN

expert video
Most Burdensome Symptoms Rated by PN Patients

Most Burdensome Symptoms Rated by PN Patients

expert video
Current systemic therapies have been shown to induce remission in a subset of AD patients

Current systemic therapies have been shown to induce remission in a subset of AD patients

expert video
Can advanced systemic therapies modify pathomechanisms in AD?

Can advanced systemic therapies modify pathomechanisms in AD?

expert video
Type 2 Inflammation at the Neuroimmune Axis in PN and CSU

Type 2 Inflammation at the Neuroimmune Axis in PN and CSU

expert video
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

expert video
Characteristics of Chronic Itch in PN and CSU

Characteristics of Chronic Itch in PN and CSU

expert video
Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU

Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU

expert video
Diagnosis of Bullous Pemphigoid Interactive Patient Case

Diagnosis of Bullous Pemphigoid Interactive Patient Case

interactivity
Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

expert video
Expert Interview: Inflammatory Cell Infiltrate and Type 2 Inflammation in PN and CSU

Expert Interview: Inflammatory Cell Infiltrate and Type 2 Inflammation in PN and CSU

expert video
Expert Interview: The Importance of Explaining Disease Pathogenesis to PN and CSU Patients

Expert Interview: The Importance of Explaining Disease Pathogenesis to PN and CSU Patients

expert video
Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

expert video
Is Pediatric AD Linked to Other Allergic Diseases?

Is Pediatric AD Linked to Other Allergic Diseases?

expert video
Itch and Inflammation in Two Distinct Diseases: PN and CSU

Itch and Inflammation in Two Distinct Diseases: PN and CSU

expert video
Long-term Impacts of AD and the Potential Benefit of Early Intervention

Long-term Impacts of AD and the Potential Benefit of Early Intervention

expert video
New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

expert video
Practical Considerations in Older Patients with AD

Practical Considerations in Older Patients with AD

expert video
Scratching May Increase Neurogenic Inflammation in PN and CSU

Scratching May Increase Neurogenic Inflammation in PN and CSU

expert video
The Benefits of Early Intervention in AD: More Than Skin Deep

The Benefits of Early Intervention in AD: More Than Skin Deep

expert video
The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

expert video
The Cumulative Disease Burden of AD in Adult Patients

The Cumulative Disease Burden of AD in Adult Patients

expert video
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Podcast

Learning objectives

  • Discuss how type 2 inflammation in atopic dermatitis is associated with the development of multiple atopic and nonatopic comorbidities that may further affect a patient’s life
  • Explore the potential of early therapeutic intervention in AD to effectively control disease activity and reduce comorbidity risk, representing a window of opportunity to alter the disease’s natural course
Tags
disease backgroundquality of lifeexpert insights
MAT-GLB-2507496 - 1.0 - 01/2026

About this expert

Dermatology

Amy Paller

MD, MS

Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US

See author’s profile
Amy Paller

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChinaChange country/region